Clinical Trials Logo

Paroxysmal Atrial Fibrillation clinical trials

View clinical trials related to Paroxysmal Atrial Fibrillation.

Filter by:

NCT ID: NCT03906461 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

LSI (Lesion Index) Workflow Observational Study

Start date: May 17, 2019
Phase:
Study type: Observational

This clinical study is a prospective, multicenter, post-market, single-arm, observational study designed to characterize the usage of the Lesion Index (LSI) with the market-released TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) in subjects with Paroxysmal Atrial Fibrillation (PAF) in a real-word environment.

NCT ID: NCT03882021 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy

WAVE-MAP AF
Start date: August 26, 2019
Phase: N/A
Study type: Interventional

The aim is to use the GRID to characterize the atrial substrate and develop a model for predicting recurrence rates after a single procedure using a PVI only approach and a contact catheter.

NCT ID: NCT03775512 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

Q-FFICIENCY
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.

NCT ID: NCT03747263 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Individualized Approach vs. Fixed Approach

INDI-FREEZE
Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The purpose of the current study is to assess differences regarding the acute efficacy, safety, procedural duration, radiation exposure and long-term success of the novel AFA-Pro in combination of an individualized shortened ablation protocol containing a reduced freezing time to the standard approach of a fixed ablation protocol in patients with symptomatic PAF.

NCT ID: NCT03714178 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation

Start date: October 20, 2018
Phase: N/A
Study type: Interventional

PEFCAT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the FARAPULSE Endocardial Ablation System for the treatment of paroxysmal atrial fibrillation.

NCT ID: NCT03700385 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

IMPULSE: A Safety and Feasibility Study of the IOWA Approach Endocardial Ablation System to Treat Atrial Fibrillation

Start date: January 19, 2018
Phase: N/A
Study type: Interventional

IMPULSE is a prospective, single-arm, multi-center, safety and feasibility study evaluating the IOWA Approach Endocardial Ablation System (FARAPULSE, Inc.) for the treatment of paroxysmal atrial fibrillation.

NCT ID: NCT03700372 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System

IMPACT
Start date: December 13, 2017
Phase:
Study type: Interventional

IMPACT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the IOWA Approach Cardiac Ablation System (FARAPULSE, Inc.) for the treatment of paroxysmal atrial fibrillation.

NCT ID: NCT03639597 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Clinical Investigation of the VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation

VALUE
Start date: January 18, 2016
Phase: N/A
Study type: Interventional

The study is a single center, open-label, single arm, prospective pre-market study designed to assess the safety and efficacy of the VytronUS Ablation System (VAS) for the treatment of atrial fibrillation in patients with drug refractory, recurrent, symptomatic, paroxysmal atrial fibrillation.

NCT ID: NCT03624881 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

Start date: September 4, 2018
Phase: Phase 4
Study type: Interventional

Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to an historical control performance goal. A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280) enrolled subjects will be treated using the STSF catheter with EPU and 50 subjects will be treated using the ST catheter with EPU. Prior to enrollment, a few sites will be selected to only enroll subjects who will be treated with the ST catheter and the remaining sites will only enroll subjects who will be treated with the STSF catheter. Bayesian adaptive design will be used to assess early success at up to two interims: one after all subjects have completed the 3- month follow-up assessment, and a second to occur after all subjects have completed the 6 months follow-up visit.

NCT ID: NCT03462628 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Additional Low Voltage Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation

STABLE-SR-III
Start date: April 24, 2018
Phase: N/A
Study type: Interventional

The primary objective of this investigation is to compare the efficacy of two different AF ablation strategies in older patients with paroxysmal AF: Pulmonary vein isolation alone versus additional low-voltage substrate modification during sinus rhythm